Beecham's APSAC
Executive Summary
A study comparing a two minute injection of the anti-thrombosis agent APSAC with a one hour injection of intra-coronary streptokinase is now underway at 15 hospitals, including the University of Rochester and the University of Utah. Beecham states that its new clot-dissolving agent "differs from other investigational and existing drugs in that it can be administered in a single five-minute injection into a vein." In a recent Phase II dose-response study of 29 heart attack patients conducted by Victor Marder, University of Rochester, the drug dissolved coronary clots in about 60% of the patients. . . .
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.